Drug Trial Radar · NCT07029568
A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People
Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Jun 13, 2025
Primary completion
Nov 4, 2025
Study completion Dec 10, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is testing a new study medicine (called NNC0705-0001), as a potential medicine to treat chronic systemic inflammation, which is known for increasing the risk of developing cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in our body, and what our body does to the study medicine. The participant will either get NNC0705-0001 or placebo (a "dummy medicine" without the active ingredient). Which treatment the participant gets is decided by chance. The study consists of 3 parts: PART A - single ascending dose (SAD); PART B - multiple ascending doses (MAD) and PART C - food effect (FE) on the pharmacokinetic (PK) properties of NNC0705-0001 and will last about 35 days (PART A) and 41 days (PART B and C).
Conditions
- Healthy Volunteers
- Chronic Kidney Disease
Interventions
NNC0705-0001Drug
NNC0705-0001 will be administered orally.
PlaceboDrug
Placebo matching NNC0705-0001 will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PART A: Number of treatment emergent adverse events (TEAE)Time frame: From time of dosing (day 1) to end of study (day 7)
- PART B: Number of TEAEsTime frame: From time of dosing (day 1) to end of study (day 13)
- AUC, SD; the area under the NNC0705-0001 plasma concentration-time curve after a single doseTime frame: From pre-dose (day 1 or day 8) to day 2 or day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON - location Groningen
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.